Kornimate/medical-research-clean huggingface dataset:
efficacy of using 3d motion tracking toothbrush in dental plaque control

Conditions: Toothbrushing

Summary: the objective of this study was to compare the efficacy of computer-assisted tbi (toothbrushing instruction) using a smart toothbrush and smart mirror (stm system) in plaque control to that of conventional tbi.

the stm system comprises a smart mirror, which is integrated into a computer monitor, and a 3d motion-capture device inside of a modified toothbrush holder. the computer program displays a toothbrushing animation in the mirror. toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis. the investigators evaluated the efficacy of tbi with a stm system by analyzing the reductions of the modified quigley-hein plaque index in 1. st study - 60 volunteers (adults) - the data for which have been published (reference) 2. nd study - 42 volunteers (schoolchildren) - manuscript prepared 3. rd study - 60 volunteers (adults and children) these participants were separated randomly into two groups: conventional tbi (control group) and stm system tbi (experimental group). the changes in the plaque indexes were recorded immediately, 1 week, 1 month, and 10 months (1st study only) after tbi.

Eligibility criteria:
inclusion criteria: * participants with poor oral conditions need more toothbrush instruction * participants were required to have their gingivitis and baseline plaque scores \>1.5 (the turesky modification of the quigley-hein index) exclusion criteria: * if they had gross dental caries or orthodontic appliances, or were medically compromised.

Keywords: teledentistry schoolchildren oral hygiene computer smart toothbrush dental plaque
pearl index study with low dose combined oral contraceptive

Conditions: Contraception

Summary: the purpose of this study is to investigate the contraceptive efficacy, bleeding pattern, and safety of sh d00342a. subjects participating in the study will be treated with an oral contraceptive pill containing 0.03 mg ethinylestradiol and 0.125 mg levonorgestrel.

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany.bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * healthy women requiring contraception exclusion criteria: * pregnant or lactating women, history or suspicion of hormone dependent tumor or any other conditions which forbid the participation.

Keywords: contraception
fondaparinux in patients with acute heparin-induced thrombocytopenia (hit)

Conditions: Heparin-Induced Thrombocytopenia

Summary: the purpose of this study is to test the safety and efficacy of fondaparinux in patients with heparin-induced thrombocytopenia (hit). the primary objective is to ensure that patients with hit who are treated with fondaparinux experience a prompt and complete recovery of their platelet count, and the secondary objective is to determine if any new blood clots are formed while receiving the fondaparinux and up to one month after study enrollment. this information will be compared to a historical control.


Eligibility criteria:
inclusion criteria: * male or female at least 18 years of age; * if female of childbearing potential, negative pregnancy test result; * diagnosis of hit confirmed by the following: decreased platelet count by 50% or greater or platelets \< 100,000/mm3 during or within 2 weeks after heparin exposure and/or new thromboembolic complications during or within 2 weeks after heparin exposure; * laboratory confirmation (either heparin pf4 antibody or serotonin release assay positive). exclusion criteria: * estimated creatinine clearance less than 30 ml/min (either measured or by using cockcroft gault equation); * pregnancy or lactating; * blood dyscrasia other than hit; * history of thrombocytopenia associated with fondaparinux; * recent (within 6 weeks) or planned surgery of cns, eye or traumatic surgery resulting in large open surfaces or other procedures with high bleeding risk or if lumbar puncture is planned; * active bleeding of gi tract, gu tract, cns or respiratory tract; * malignant hypertension, pericarditis, pericardial effusion, endocarditis or eclampsia; * inadequate laboratory facilities, inadequate support system at home, alcoholism, drug abuse, psychosis or dementia; * hypersensitivity or contraindication to warfarin or fondaparinux.

Keywords: heparin-induced thrombocytopenia fondaparinux
transcutaneous auricular vagus nerve stimulation (tavns) in chronic kidney disease (ckd)

Conditions: Chronic Kidney Diseases

Summary: 30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (tavns) for autonomic nervous system (ans) dysfunction in the chronic kidney disease (ckd) stage 3-5 setting.


Eligibility criteria:
inclusion criteria: * individuals age ≥18 years * diagnosis of chronic kidney disease (ckd) stage 3-5 \[estimated glomerular filtration rate \&le;60 ml/min/1.73m2\] * receiving care at nyu nephrology outpatient practice * able to provide informed consent exclusion criteria: * primary ans disorders (e.g., parkinson's disease) * arrhythmias * implantable cardioverter-defibrillator (icd) or pacemaker (ppm) precluding assessment of hrv (e.g., chronic atrial fibrillation) * on maintenance dialysis (hd) * epilepsy * symptomatic bradycardia * presence of an implantable defibrillators * presence of a permanent pacemaker * unable to consent * incarcerated individuals * pregnant individuals
individualized bowel preparation for colonoscopy

Conditions: Colon Disease

Summary: a randomized control trial comparing a standard bowel preparation for colonoscopy with an individualized bowel preparation strategy based on patient characteristics


Eligibility criteria:
inclusion criteria: * elective out-patient diagnostic or therapeutic colonoscopy exclusion criteria: * pregnant women; refusal to participate; significant comorbidities (asa score 3 or above); suspicion of bowel perforation;
holding a foster child's mind in mind

Conditions: Attachment Disorder; Behavior Problem

Summary: the aim of this study is to examine the effects of mentalization based therapy (mbt) for foster families in denmark on child mental health and well-being, parental stress, mental health, and reflective function, parental mind-mindedness and the parent-child relationship.

children placed in foster care are psychologically and physically vulnerable and show more social, developmental, and behavioral problems than children living with their family of origin. many foster parents struggle to care for these children, some of whom have experienced serious adversity at a young age. the study examines the effects of mentalization based therapy (mbt) in a cluster-randomized controlled trial with 175 foster families with children aged 4-17 years in 10 danish municipalities.

Eligibility criteria:
inclusion criteria: * any kind of foster family (including professional and kinship care) with at least one full-time foster child aged 4-17 years. * elevated child symptoms as measured by x scales and * an expressed need for support from either the foster parents or the foster child. exclusion criteria: * foster families in which there are no reported difficulties and concerns regarding the child or the placement. * foster families in which the child was placed with the family within the last x months

Keywords: foster care mentalization therapy attachment effects
advanced glycation end products as a biomarker for accelerated ageing

Conditions: Primary Open Angle Glaucoma; Normal Tension Glaucoma; Ocular Hypertension

Summary: globally primary open angle glaucoma (poag) affects over 60 million people. the exact pathogenesis of poag is poorly understood. a significant risk factor for glaucoma is advancing age. the rate of ageing is not the same in all age matched individuals. the concept of accelerated ageing suggests that the presence of a number of specific genetic, environmental or systemic risk factors may cumulate to accelerate the ageing process in some individuals and lead to the development of age-related disease. understanding the factors that influence accelerated ageing is vital. advanced glycation end products (ages) are a complex group of compounds that are naturally formed. they accumulate gradually with age in cells, tissues and blood vessels throughout the body where they adversely affect structure and function. circulating age levels can be influenced by oxidative stress levels and dietary intake. recent research has found that sustained exposure to high levels of circulating ages could be a major factor in the development of a number of chronic age-related degenerative disorders, including poag. to date there have been few clinical studies that have been able to non-invasively explore the association between age levels and the development and progression of glaucomatous optic neuropathy (gon), or to explore the possible contribution that oxidative stress and dietary intake make to total tissue age levels in such patients. furthermore little is understood about the relationship between age levels and retinal vascular function, a parameter known to be altered in gon that also could be influenced by age levels. the proposed study will aim to evaluate whether tissue-bound age levels are associated with parameters of retinal vascular function, oxidative stress, dietary intake and the presence of gon. establishing this association could increase our understanding of the pathogenesis of gon and allow a new biomarker for accelerated ocular ageing to be realised


Eligibility criteria:
inclusion criteria: * must have had an eye test within the last two years * aged 50+ * informed, written consent * have adequate understanding of english language to be able to comprehend the oral and written instructions. * participants must be able to complete a 12-hour overnight fast, which includes no alcohol or caffeine. inclusion criteria for ocular hypertension, primary open angle glaucoma and normal tension glaucoma: - follows guidelines set out within the protocol and used at derriford rei exclusion criteria: * diabetes * current smokers * history of stroke/tia * coronary artery disease/heart failure/arrhythmia/angina * peripheral vascular disease * severe dyslipidaemia * hyper/hypothyroidism
functional brain imaging - acupuncture and osteoarthritis

Conditions: Osteoarthritis

Summary: the goal of this study is to use single photon emission computed tomography (spect) and functional magnetic resonance imaging (f-mri) of the brain to study the response of both normal participants and participants with osteoarthritis (oa) of the knee to acupuncture.

recent experimental studies in both animal and humans have begun to demonstrate some measurable physiologic effects that are associated with acupuncture, suggesting the possibility of a neurophysiologic explanation. in addition, brain research continues to uncover a complex set of endogenous neurologic control systems, such that it has become clear that the brain plays a major role in the modulation of pain perception and control. if acupuncture can be demonstrated to have a consistent effect on specific areas of the brain, it will become possible to explore the potential efficacy of acupuncture based on measurable neurophysiologic responses.

Eligibility criteria:
inclusion criteria: * seen in an outpatient clinical setting * have active knee oa of \>6 months including kellgren x-ray changes \>2 from an x-ray report \<12 months old or new x-ray interpretation * moderate unilateral only pain (average \>4/10 on a 0-10 likert scale) for more than 5 out of 7 days * have the capacity to understand the requirements of the study and complete the baseline studies in a reasonable time frame, as determined by the interviewer exclusion criteria: * having had acupuncture before (must be acupuncture naïve) * any history of claustrophobia that could affect the subject's ability to tolerate the f-mri study * hip or ankle disease by history or exam severe enough to cause pain \>2/10 daily * bleeding disorder or current use of warfarin or heparin by patient history * other primary causes of chronic knee pain, per the referring physician, including chondromalacia patella, torn meniscus or ligament injury.

Keywords: acupuncture spect f-mri functional brain imaging rct
glycemic response in adults with diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this will be a randomized crossover design with oral nutrition supplement interventions.

this will be a randomized crossover design with two oral nutrition supplement interventions. the subjects will be randomized to one of two interventions on two separate study days, one week apart.

Eligibility criteria:
inclusion criteria: * age 20-75 years * type 2 diabetes controlled with diet or diet and metformin (glucophage) * hemoglobin a1c less than 9.0% * fasting blood glucose less than 180 mg/dl * hematocrit levels within normal limits * having obtained his/her informed consent exclusion criteria: * abnormal thyroid function * creatinine \>2.0 mg/dl * potassium \<3.5 meq/l * gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting * currently unstable diabetes or under treatment for cancer, heart disease, renal disease * patients with anemia * current insulin therapy or insulin therapy within the past month * patient who are pregnant * allergies to milk, soy or any component of the test product * patient who in the investigators assessment cannot be expected to comply with treatment * patients with anemia * currently participating in another clinical trial
comparison of volume controlled ventilation and autoflow-volume controlled ventilation in robot-assisted laparoscopic radical prostatectomy with steep trendelenburg position and pneumoperitoneum

Conditions: Robot-assisted Laparoscopic Radical Prostatectomy Undergoing General Anesthesia

Summary: the steep trendelenburg position and pneumoperitoneum during laparoscopic surgery have the potential to cause an adverse effects on respiratory mechanics and gas exchange. autoflow-volume controlled ventilation may improve lung compliance and reduce airway peak pressure. therefore, the aim of this study is to evaluate whether autoflow-volume controlled ventilation improves gas exchange and respiratory mechanics in patients undergoing robot-assisted laparoscopic radical prostatectomy.


Eligibility criteria:
inclusion criteria: 1. adult male patients scheduled for elective robot-assisted laparoscopic radical prostatectomy undergoing general anesthesia exclusion criteria: 1. chronic obstructive respiratory diseases 2. heart failure 3. body mass index (bmi \>30 kg/m2)

Keywords: robot-assisted laparoscopic radical prostatectomy autoflow trendelenburg position pneumoperitoneum
68ga-rm26-rgd pet/ct imaging in the grpr and αvβ3 positive tumor patients

Conditions: Breast Cancer; Prostate Cancer; Brain Tumor; PET/CT Imaging

Summary: based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. in this study, a novel dual-target imaging agent 68ga-rm26-rgd was used for clinical study of tumor pet/ct imaging to further verify its clinical application value.

conventional 18f-fdg pet/ct has important diagnostic value in cell metabolism level, early metastasis, judging malignant potential and prognosis of tumors. it has been routinely used for staging and restaging of most tumors, but there are still some tumors with low uptake of 18f-fdg pet/ct. receptor imaging with a single target also has some limitations in clinical application. for example, not all diseased cells express a large amount of single receptor on the surface, which greatly affects the judgment of the nature of the lesion. the dual-target molecular imaging based on grpr expressed in the lesion site and integrin αvβ3 receptor highly expressed on the surface of the lesion neovascularization will overcome the above limitations and make full use of the advantages of the dual-target molecular imaging, which will greatly assist the diagnosis of malignant tumors such as breast\\brain\\prostate tumor which have high grpr and αvβ3 receptor expression . in this study, a novel dual-target imaging agent 68ga-rm26-rgd was used for pet/ct imaging of breast\\brain\\prostate cancer, compared with conventional 18f-fdg, or single target imaging agent 68ga-rgd or 68ga-rm26 pet/ct imaging.

Eligibility criteria:
inclusion criteria: * patients with confirmed or suspected breast/brain/prostate cancer; * 68ga-rm26-rgd and 18f-fdg(or 68ga-rm26 or 68ga-rgd) pet/ct within 2 week; * signed written consent. exclusion criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
level of continuous positive airway pressure (cpap) in preterm infants after extubation (l-cpap study)

Conditions: Respiratory Insufficiency of Prematurity

Summary: despite widely used of nasal cpap in preterm infants, uncertainties regarding aspects of its application remain. clinical indications vary greatly between institutions, especially when combined with varieties of systems, devices, and techniques available. one of the controversial aspects that needs to be clarified is the level of pressure which should be used. the objective of the study is to compare the effectiveness of two ranges of ncpap pressure that are within the spectrum of current practice for post-extubation support in very preterm infants.

the use of ncpap has been established as an effective respiratory support to prevent extubation failure and as treatment of other pulmonary diseases. an upsurge in its popularity has resulted in some controversial aspects, including the level of pressure to be used. the level that has been used in very preterm infants after extubation, which mostly came from anecdotal data, varies from 3 to 10 cmh2o. physiologic studies show higher ncpap pressures improve lung mechanical properties. though potential side effects have been of concern in practical application, there is no formal evidence supporting the concept that increased cpap pressure results in a higher risk of complications. in relatively stable preterm infants, the range of optimal cpap level needs to be established in order to adequately support the upper airway and lungs, without increasing complications secondary to the pressure applied. given the uncertainty of the ncpap pressure that should be used in very preterm infants, we conduct a randomized controlled trial to compare the effectiveness of two ranges of ncpap pressure for post-extubation support in very preterm infants. the purpose of this trial is to compare the rate of successful extubation of using the nasal cpap level of 7 to 9 cmh2o compared to level of 4 to 6 cmh2o.

Eligibility criteria:
inclusion criteria: * birth weight 500 - 1,250 g * on mechanical ventilation before 7 days of age * first extubation before 14 days of age exclusion criteria: * presence of lethal anomalies or upper airway abnormalities * ivh, grade 3 or 4 * neuromuscular disorders * receiving muscle relaxation at time of extubation * congenital heart disease, except for pda * gi problems resulting in a need to avoid gastric distension

Keywords: respiratory distress syndrome preterm infants extubation failure pneumothorax lung injury airway pressure
antineoplaston therapy in treating patients with stomach cancer

Conditions: Stomach (Gastric) Cancer

Summary: current therapies for stomach cancer provide very limited benefit to the patient. the anti-cancer properties of antineoplaston therapy suggest that it may prove beneficial in the treatment of stomach cancer. purpose: this study is being performed to determine the effects (good and bad) that antineoplaston therapy has on patients with stomach cancer.

stomach cancer cancer patients receive gradually escalating doses of intravenous antineoplaston therapy (atengenal + astugenal) until the maximum tolerated dose is reached. treatment continues up to12 months in the absence of disease progression or unacceptable toxicity. objectives: * to determine the efficacy of antineoplaston therapy in patients with stomach cancer, as measured by an objective response to therapy (complete response, partial response or stable disease). * to determine the safety and tolerance of antineoplaston therapy in patients with stomach cancer. * to determine objective response, tumor size is measured utilizing mri scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter.

Eligibility criteria:
disease characteristics: * histologically proven adenocarcinoma of the stomach that is unlikely to respond to existing therapy, including surgery, radiotherapy, and chemotherapy * evidence of tumor by mri, ct scan, chest x-ray, or radionuclide scan patient characteristics: age: * 18 and over performance status: * karnofsky 60-100% life expectancy: * at least 2 months hematopoietic: * wbc at least 2,000/mm\^3 * platelet count at least 50,000/mm\^3 hepatic: * no hepatic insufficiency * bilirubin no greater than 2.5 mg/dl * sgot and sgpt no greater than 5 times upper limit of normal renal: * no renal insufficiency * creatinine no greater than 2.5 mg/dl * no history of renal conditions that contraindicate high dosages of sodium cardiovascular: * no known chronic heart failure * no uncontrolled hypertension * no history of congestive heart failure * no history of other cardiovascular conditions that contraindicate high dosages of sodium pulmonary: * no serious lung disease, such as chronic obstructive pulmonary disease other: * not pregnant or nursing * fertile patients must use effective contraception during and for 4 weeks after study participation * not a high medical or psychiatric risk * no concurrent nonmalignant systemic disease * no active infection prior concurrent therapy: biologic therapy: * at least 4 weeks since prior immunotherapy * no concurrent immunomodulating agents chemotherapy: * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered endocrine therapy: * concurrent corticosteroids allowed radiotherapy: * at least 8 weeks since prior radiotherapy and recovered surgery: * recovered from prior surgery other: * prior cytodifferentiating agents allowed * no other concurrent antineoplastic agents

Keywords: stage iii and iv stomach (gastric) cancer recurrent stomach (gastric) cancer